ONC 7
Alternative Names: ONC-7Latest Information Update: 21 Jul 2023
At a glance
- Originator Cyrus Therapeutics
- Developer Cyrus Therapeutics; GC Biopharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Haematological malignancies; Solid tumours
Most Recent Events
- 04 Jul 2023 Early research in Haematological malignancies in South Korea (unspecified route) (Cyrus Therapeutics pipeline, July 2023)
- 04 Jul 2023 Early research in Solid tumours in South Korea (unspecified route) (Cyrus Therapeutics pipeline, July 2023)